Sensus Healthcare - SRTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 62.07%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$6.17
▲ +0.48 (8.44%)

This chart shows the closing price for SRTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensus Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRTS

Analyst Price Target is $10.00
▲ +62.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sensus Healthcare in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 62.07% upside from the last price of $6.17.

This chart shows the closing price for SRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Sensus Healthcare. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/12/2024Roth CapitalUpgradeStrong-BuyN/A
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $10.00Low
5/10/2024Maxim GroupBoost TargetBuy ➝ Buy$7.00 ➝ $10.00Low
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $8.00Low
5/4/2023HC WainwrightLower Target$16.00 ➝ $10.00Low
5/4/2023Alliance Global PartnersLower Target$14.50 ➝ $7.00Low
2/10/2023Maxim GroupReiterated RatingBuy$20.00Low
2/10/2023HC WainwrightReiterated RatingBuy$16.00Low
2/10/2023Alliance Global PartnersLower TargetBuy$16.50 ➝ $14.50Low
11/4/2022Alliance Global PartnersLower TargetBuy$17.50 ➝ $16.50Low
5/6/2022Maxim GroupReiterated RatingBuy$14.00High
3/3/2022HC WainwrightBoost TargetBuy$12.00 ➝ $13.00High
2/14/2022HC WainwrightBoost TargetBuy$10.00 ➝ $12.00High
2/11/2022Maxim GroupInitiated CoverageBuy$12.00High
1/6/2022HC WainwrightReiterated RatingBuy$10.00Low
1/6/2022Maxim GroupBoost TargetBuy ➝ Buy$7.00 ➝ $12.00High
12/2/2021HC WainwrightBoost TargetBuy$9.00 ➝ $10.00High
11/5/2021Maxim GroupReiterated RatingBuy$7.00Medium
11/5/2021HC WainwrightBoost TargetBuy$7.00 ➝ $9.00High
8/6/2021HC WainwrightBoost TargetBuy$6.00 ➝ $7.00High
5/7/2021Maxim GroupReiterated RatingBuy$6.00Medium
3/1/2021HC WainwrightBoost TargetBuy$4.00 ➝ $6.00Low
2/26/2021Roth CapitalBoost TargetBuy$4.00 ➝ $6.00High
2/26/2021Northland SecuritiesUpgradeMarket Perform ➝ OutperformHigh
12/16/2020Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
11/9/2020HC WainwrightLower TargetBuy$5.00 ➝ $4.00High
11/6/2020Maxim GroupReiterated RatingBuy$6.00High
8/10/2020Alliance Global PartnersUpgradeNeutral ➝ Buy$2.40 ➝ $4.25High
8/7/2020HC WainwrightReiterated RatingBuy$5.00Low
6/4/2020Northland SecuritiesInitiated CoverageBuy$4.65Low
5/11/2020B. RileyLower TargetNeutral$5.50 ➝ $3.00Medium
5/8/2020Maxim GroupReiterated RatingBuy$6.00Medium
5/8/2020HC WainwrightLower TargetBuy$8.00 ➝ $5.00Medium
5/6/2020Alliance Global PartnersDowngradeBuy ➝ Neutral$6.00 ➝ $2.40High
2/14/2020Alliance Global PartnersUpgradeNeutral ➝ Buy$6.00High
2/14/2020HC WainwrightLower TargetBuy$10.00 ➝ $8.00Medium
11/7/2019B. RileyDowngradeBuy ➝ Neutral$14.00 ➝ $5.50High
11/7/2019HC WainwrightReiterated RatingBuy$10.00High
8/9/2019Maxim GroupSet TargetBuy$11.00Medium
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 11 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sensus Healthcare logo
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Read More

Today's Range

Now: $6.17
Low: $5.71
High: $6.32

50 Day Range

MA: $5.37
Low: $3.76
High: $6.42

52 Week Range

Now: $6.17
Low: $1.79
High: $6.55

Volume

273,486 shs

Average Volume

117,064 shs

Market Capitalization

$101.13 million

P/E Ratio

21.28

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensus Healthcare?

The following Wall Street sell-side analysts have issued reports on Sensus Healthcare in the last twelve months: HC Wainwright, Maxim Group, Roth Capital, and TheStreet.
View the latest analyst ratings for SRTS.

What is the current price target for Sensus Healthcare?

2 Wall Street analysts have set twelve-month price targets for Sensus Healthcare in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 62.1%. Maxim Group has the highest price target set, predicting SRTS will reach $10.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $10.00 for Sensus Healthcare in the next year.
View the latest price targets for SRTS.

What is the current consensus analyst rating for Sensus Healthcare?

Sensus Healthcare currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRTS will outperform the market and that investors should add to their positions of Sensus Healthcare.
View the latest ratings for SRTS.

What other companies compete with Sensus Healthcare?

How do I contact Sensus Healthcare's investor relations team?

Sensus Healthcare's physical mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company's listed phone number is (561) 922-5808 and its investor relations email address is [email protected]. The official website for Sensus Healthcare is www.sensushealthcare.com. Learn More about contacing Sensus Healthcare investor relations.